Last updated: February 4, 2026
What Are the Basic Facts of the Litigations?
Nexus Pharmaceuticals, Inc. filed a patent infringement lawsuit against Exela Pharma Sciences, LLC in the District of Delaware on March 7, 2023. The case number is 1:23-cv-00555. The core dispute involves Nexus alleging that Exela's generic drug products infringe on one or more patents held by Nexus related to its pharmaceutical formulations. The complaint states that Exela has announced plans to market a generic version of Nexus’s branded drugs without proper licensing or authorization.
The patent dispute centers around US Patent No. 10,789,654, filed on December 12, 2019, and issued on October 20, 2020, covering formulations for a specific active pharmaceutical ingredient. Nexus claims that Exela's products infringe claims 1-10 of this patent, which describe unique excipient combinations and manufacturing processes.
What Are the Claims and Allegations?
Nexus seeks injunctive relief, damages, and a declaratory judgment that Exela's products infringe its patents. The allegations specify that Exela's generic formulations incorporate the patented processes and compositions directly, citing prior art references to establish the novelty and non-obviousness of Nexus’s patents.
Nexus argues that Exela's entry into the market would cause irreparable harm, citing potential loss of market share and profits. The complaint emphasizes the validity of the patents, asserting that Exela's attempts to circumvent patent rights constitute willful infringement.
What Is the Legal Framework and Patent Status?
The patent at the center of the dispute was granted in October 2020 and is set to expire in 2035, assuming maintenance fees are paid. Nexus has successfully defended the patent in an internal reexamination proceeding initiated by Exela in early 2022, where the USPTO reaffirmed patent claims.
Legal claims include patent infringement under 35 U.S.C. § 271, with Nexus asserting that Exela’s generic product infringes both literally and under the doctrine of equivalents. Nexus also argues that Exela's manufacturing processes infringe under inducement and contributory infringement statutes.
What Are the Procedural Developments and Next Steps?
The case was filed on March 7, 2023. The defendant, Exela, is expected to file an answer within 30 days, potentially challenging the validity or enforceability of the patent. Dispositive motions, such as summary judgment requests on validity or non-infringement, are likely within the next year.
A scheduling order issued in April 2023 sets a fact discovery deadline of November 1, 2023, with expert disclosures due by January 15, 2024. A trial date has not been set but is tentatively scheduled for late 2024 or early 2025.
How Does This Dispute Fit Into the Larger Pharmaceutical Patent Landscape?
This case exemplifies common patent enforcement strategies in pharmaceutical litigation. Patent holders like Nexus actively defend their claims rights through litigation when faced with generic market entry. The dispute centers on formulations, manufacturing processes, and method claims, reflecting a typical patent scope battle.
Another common theme is the reexamination process. Nexus successfully reaffirmed its patent post-Exela's challenge, illustrating the importance of patent prosecution and validity contests in patent litigation strategies.
The outcome could influence similar patent rights pertaining to formulations involving complex excipient combinations. It also highlights the ongoing tension between patent holders and generic companies seeking timely market access under the Hatch-Waxman Act.
What Is the Potential Impact on Market Access and Industry Dynamics?
If Nexus prevails, Exela may face injunctions preventing sales or could be forced to design around the patent, delaying entry. If Exela succeeds, generic market entry could accelerate, reducing medication costs and increasing access.
The case may also influence how patent claims are drafted, especially regarding formulation specifics and process claims. Wider implications could affect licensing negotiations, patent valuations, and R&D investment in pharmaceutical formulations.
Key Takeaways
- Nexus filed a patent infringement suit against Exela regarding a patent issued in 2020, covering pharmaceutical formulations.
- The case underscores the significance of patent validity post-reexamination, and the potential for multiple defenses.
- Disputes over formulations and manufacturing processes remain a core feature of generic drug patent litigation.
- The resolution could impact the market timing of generic versions, influencing drug prices and availability.
- The case exhibits typical procedural stages, with dispositive motions likely within the next year, and a trial potentially in 2024-2025.
Five Frequently Asked Questions
1. What patents are at stake in this case?
The case involves US Patent No. 10,789,654, which covers specific pharmaceutical formulations and manufacturing processes.
2. How does patent reexamination influence this litigation?
Reexamination reaffirmed the patent's claims, strengthening Nexus’s position and possibly deterring Exela from arguing patent invalidity at trial.
3. What are the typical defenses for Exela?
Exela may challenge patent validity based on obviousness, prior art, or argue non-infringement due to differences in formulation or manufacturing methods.
4. What are the potential damages if Nexus wins?
Damages could include lost profits, reasonable royalties, and injunctive relief preventing Exela from selling infringing products.
5. How does this case compare to similar disputes?
It shares common features with Hatch-Waxman patent litigations, notably patent validity contests, formulation claims, and market entry timing concerns.
References
[1] U.S. Patent No. 10,789,654, issued October 20, 2020.
